Many agents developed for neuroprotective treatment of Parkinson disease (PD) have
shown great promise in the laboratory, but none have translated to positive results in …

Recent research in the pharmacotherapy of Parkinson's disease (PD) has been able to
provide numerous agents for the symptomatic control of motor impairments, but has failed to …

Background: Current therapies for PD ameliorate symptoms in the early phases of disease
but become less effective over time, as the underlying disease progresses. Therapies that …

Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …

Promising disease-modifying therapies for Parkinson’s disease | Science Translational
Medicine news careers commentary Journals Science Science brought to you byGoogle Indexer …

The development of a neuroprotective therapy that slows, stops, or reverses
neurodegeneration in Parkinson's disease (PD) is the single most important unresolved …

Our current wish list for the treatment of Parkinson's disease (PD) includes therapies that will
provide robust and sustained antiparkinsonian benefit through the day, ameliorate or …

Parkinson's disease (PD) is the second most common neurodegenerative disorder after
Alzheimer's disease and is an important cause of chronic disability. Numerous important …

Parkinson's disease (PD) is one of the common chronic degenerative conditions of the
nervous system. There is currently no cure for PD, but a number of drugs offer benefits in …

Parkinson's disease (PD) is a progressive neurodegenerative disorder. Although therapies
that treat the symptoms of the disease have proven efficacy, strategies that slow or stop the …